Indeed, there are extremely few high-quality mechanistic studies on other signature genes (e.g., CSTF2, APOM, and KRT6C) that may serve as targets for subsequent studies on the molecular mechanisms of pancreatic cancer. This evidence concerns the gene KRT6C and familial pancreatic carcinoma.